Motor Neuron Disease Clinical Trial
Official title:
Safety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I Trial
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that
selectively affects motor neurons in the brain and spinal cord, leading to bulbar,
respiratory, and limb weakness. There is no effective treatment, and the disease usually
progresses to death within 2 to 4 years. The therapeutic plasticity of mesenchymal stem cells
(MSCs) may be an attractive therapy to this complex disease, turning MSCs strong candidates
for cellular therapy in ALS.
Design—A phase 1 open-safety clinical trial. 4 patients will be selected according to a
restricted inclusion and exclusion criteria and after 2 escalated infusions of MSCs, there
will be a follow up period of one year Methods - Primary endpoint: safety of mesenchymal
autologous stem cells infusions escalated in two intrathecal administrations in patients with
ALS defined as severe adverse events (SAe). Secondary endpoints: clinical response,
laboratorial and magnetic resonance imaging of patients submitted to cellular escalating
doses applied in the study. Quality of life, according to El Escorial criteria, ALSFR scale
and functional scales.
Conclusion: This study is a primary step before a large randomized double-blind clinical
trial for ALS. It is expected to confirm the safety of escalated MSCs therapy in ALS
patients, initial data of efficacy in addition to improved quality of life.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
| Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02464748 -
Telehealth in Motor Neurone Disease
|
N/A | |
| Completed |
NCT00956488 -
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT00537446 -
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
|
N/A | |
| Recruiting |
NCT04944940 -
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
|
||
| Recruiting |
NCT03362658 -
Novel MRI Biomarkers for Monitoring Disease Progression in ALS
|
||
| Completed |
NCT00714636 -
Cerebrospinal Fluid Repository
|
N/A | |
| Completed |
NCT00076687 -
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
|
Phase 2 | |
| Completed |
NCT00071435 -
Brain Function in Primary Lateral Sclerosis
|
N/A | |
| Completed |
NCT00001220 -
Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders
|
N/A | |
| Completed |
NCT03487263 -
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
|
Phase 1 | |
| Enrolling by invitation |
NCT05725759 -
Rehabilitation in SOD1 ALS Treated With Tofersen
|
||
| Active, not recruiting |
NCT03811301 -
[BrainConnexion] - Neurodevice Phase I Trial
|
N/A | |
| Completed |
NCT02469896 -
A Trial of Tocilizumab in ALS Subjects
|
Phase 2 | |
| Completed |
NCT02011204 -
Study of Electrical Impedance Myography (EIM) in ALS
|
N/A | |
| Completed |
NCT01495390 -
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
|
N/A | |
| Completed |
NCT02870634 -
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
|
Phase 1 | |
| Recruiting |
NCT06201650 -
Neurofilament Light Chain in Amyotrophic Lateral Sclerosis
|